CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting - A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study 3D Printing and Heart Failure: The Present and the Future Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential Second vs. First generation drug eluting stents in multiple vessel disease and left main stenosis: Two-year follow-up of the observational, prospective, controlled, and multicenter ERACI IV registry

Clinical Trial15 Nov 2021

JOURNAL:Circulation. Article Link

Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

J Butler, G Filippatos, TJ Siddiqi et al. Keywords: HFpEF; empagliflozin; health status

Full Text PDF